Solid biosciences inc. (SLDB)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Assets
Current assets:
Cash and cash equivalents

53,187

76,043

94,720

51,836

53,994

86,366

129,137

145,824

164,773

52,080

Available-for-sale-securities

400

7,481

10,943

15,550

-

36,098

-

-

-

17,014

Available-for-sale-securities

-

-

-

-

40,750

-

16,232

16,935

17,609

-

Prepaid expenses and other current assets

4,316

2,778

7,829

10,935

7,043

6,175

3,062

1,714

1,931

1,499

Restricted cash

-

-

-

-

-

-

0

0

65

65

Total current assets

57,903

86,302

113,492

78,321

101,787

128,639

148,431

164,473

184,378

70,658

Property and equipment, net

10,866

11,645

11,369

11,829

11,995

10,422

7,935

6,551

4,418

2,429

Operating lease, right-of-use assets

4,655

4,988

5,529

5,618

5,916

-

-

-

-

-

Other non-current assets

209

209

209

209

209

209

209

209

209

-

Restricted cash

327

327

327

327

327

327

237

237

237

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

3,106

Total assets

73,960

103,471

130,926

96,304

120,234

139,597

156,812

171,470

189,242

76,193

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

2,383

7,124

3,210

5,600

5,352

3,691

4,804

3,741

5,835

5,066

Accrued expenses

8,507

9,178

11,466

6,007

7,409

8,235

5,833

4,938

4,092

5,972

Operating lease liabilities

1,799

1,736

1,672

1,610

1,278

-

-

-

-

-

Finance lease liabilities

191

186

181

176

178

173

-

-

-

-

Other current liabilities

-

52

221

278

355

382

-

-

-

233

Total current liabilities

12,880

18,276

16,750

13,671

14,572

12,481

10,637

8,679

9,927

11,271

Operating lease liabilities, excluding current portion

3,941

4,414

4,869

5,309

5,736

-

-

-

-

-

Finance lease liabilities, excluding current portion

683

733

782

829

813

859

-

-

-

-

Other non-current liabilities

-

-

-

-

-

1,074

1,102

499

365

-

Total liabilities

17,504

23,423

22,401

19,809

21,121

14,414

11,739

9,178

10,292

11,271

Commitments and contingencies (Note 11)

-

-

-

-

-

-

0

0

0

-

Preferred Units

-

-

-

-

-

-

-

-

-

0

Stockholders’ Equity:
Series A, B, C and D Common Units, no units authorized at December 31, 2018 and 20,189,509 units authorized at December 31, 2017; no units issued and outstanding at December 31, 2018 and 19,438,552 units issued and outstanding at December 31, 2017

-

-

-

-

-

-

-

-

-

65,014

Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

0

Common stock, $0.001 par value; 300,000,000 shares authorized at March 31, 2020 and December 31, 2019; 46,070,724 shares issued and outstanding at March 31, 2020 and 45,987,571 shares issued and outstanding at December 31, 2019; 2,295,699 pre-funded warrants outstanding at March 31, 2020 and December 31, 2019

48

48

48

35

35

35

35

35

35

-

Additional paid-in capital

399,382

396,278

392,897

331,620

327,709

324,209

322,179

320,382

319,073

-

Accumulated other comprehensive (loss) gain

-1

1

-2

3

7

-5

-6

-10

-23

-13

Accumulated deficit

-342,973

-316,279

-284,418

-255,163

-228,638

-199,056

-177,135

-158,115

-140,135

-124,258

Total stockholders'/members’ equity/(deficit)

-

-

-

-

-

-

-

-

-

-59,257

Total stockholders’ equity

56,456

80,048

108,525

76,495

99,113

125,183

145,073

162,292

178,950

-

Total liabilities and stockholders’ equity

73,960

103,471

130,926

96,304

120,234

139,597

156,812

171,470

189,242

76,193

Series 2 Senior Preferred Units [Member]
Preferred Units

-

-

-

-

-

-

-

-

-

55,002

Series 1 Senior Preferred Units [Member]
Preferred Units

-

-

-

-

-

-

-

-

-

25,000

Junior Preferred Units [Member]
Preferred Units

-

-

-

-

-

-

-

-

-

44,177